Search
Now showing items 1-1 of 1
A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial
Grunenberg, Alexander et al. (2021)
Wissenschaftlicher Artikel